Christopher Richard Anzalone Sells 50,800 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stock

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) CEO Christopher Richard Anzalone sold 50,800 shares of the business’s stock in a transaction dated Friday, April 11th. The shares were sold at an average price of $11.49, for a total transaction of $583,692.00. Following the completion of the transaction, the chief executive officer now owns 3,921,255 shares in the company, valued at approximately $45,055,219.95. This trade represents a 1.28 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Christopher Richard Anzalone also recently made the following trade(s):

• On Wednesday, April 9th, Christopher Richard Anzalone sold 40,322 shares of Arrowhead Pharmaceuticals stock. The shares were sold at an average price of $10.07, for a total transaction of $406,042.54.
• On Thursday, March 13th, Christopher Richard Anzalone sold 51,425 shares of Arrowhead Pharmaceuticals stock. The stock was sold at an average price of $15.07, for a total value of $774,974.75.
• On Tuesday, March 4th, Christopher Richard Anzalone sold 133,333 shares of Arrowhead Pharmaceuticals stock. The stock was sold at an average price of $17.02, for a total value of $2,269,327.66.

Arrowhead Pharmaceuticals Price Performance

ARWR opened at $11.79 on Friday. The company has a fifty day moving average price of $16.07 and a two-hundred day moving average price of $18.86. The company has a debt-to-equity ratio of 7.27, a quick ratio of 6.09 and a current ratio of 6.09. The firm has a market capitalization of $1.62 billion, a PE ratio of -2.28 and a beta of 0.99. Arrowhead Pharmaceuticals, Inc. has a 52 week low of $9.57 and a 52 week high of $30.41.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its quarterly earnings data on Monday, February 10th. The biotechnology company reported ($1.39) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.97). As a group, analysts anticipate that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the company. HC Wainwright restated a “buy” rating and issued a $80.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, February 12th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $42.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, February 11th. StockNews.com upgraded shares of Arrowhead Pharmaceuticals to a “sell” rating in a research report on Friday, December 20th. B. Riley reissued a “buy” rating and issued a $38.00 price target (down previously from $51.00) on shares of Arrowhead Pharmaceuticals in a report on Friday, February 14th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Tuesday, February 11th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, Arrowhead Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $41.44.

Hedge Funds Weigh In On Arrowhead Pharmaceuticals

Institutional investors have recently modified their holdings of the stock. GAMMA Investing LLC boosted its stake in Arrowhead Pharmaceuticals by 4,965.8% during the 1st quarter. GAMMA Investing LLC now owns 27,710 shares of the biotechnology company’s stock worth $3,530,000 after acquiring an additional 27,163 shares during the last quarter. Mackenzie Financial Corp bought a new stake in Arrowhead Pharmaceuticals in the fourth quarter valued at approximately $137,000. GF Fund Management CO. LTD. acquired a new stake in Arrowhead Pharmaceuticals in the fourth quarter worth $49,000. Neo Ivy Capital Management acquired a new position in shares of Arrowhead Pharmaceuticals in the 4th quarter valued at $318,000. Finally, Two Sigma Advisers LP grew its holdings in shares of Arrowhead Pharmaceuticals by 330.7% in the 4th quarter. Two Sigma Advisers LP now owns 430,700 shares of the biotechnology company’s stock valued at $8,097,000 after buying an additional 330,700 shares during the period. 62.61% of the stock is currently owned by institutional investors and hedge funds.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.